MedTrace Logo

A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects

NCT05943886 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2023-07-17

No results posted yet for this study

Summary

This is a single-center, randomized, double-blind, placebo-controlled, escalating single-dose and multiple-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HEC88473 injection in healthy subjects, obese subjects and subjects with type 2 diabetes mellitus (T2DM).

Conditions

  • Healthy Subjects
  • Obesity
  • T2DM (Type 2 Diabetes Mellitus)

Interventions

DRUG

HEC88473 injection

HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.

DRUG

Placebo

Placebo will be administered by subcutaneous injection in the abdomen.

Sponsors & Collaborators

  • Dongguan HEC Biopharmaceutical R&D Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yanhua Ding, Doctor · The First Hospital of Jilin University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-11
Primary Completion
2023-02-17
Completion
2023-02-17

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05943886 on ClinicalTrials.gov